20:01 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

Looking to advance several clinical candidates, Galecto Biotech AB (Copenhagen, Denmark) raised €79 million ($91.1 million) on Oct. 26 in a tranched series C round. Galecto CEO Hans Schambye declined to disclose details regarding the...
06:02 , Oct 26, 2018 |  BC Extra  |  Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

Looking to advance several clinical candidates, Galecto Biotech AB (Copenhagen, Denmark) raised €79 million ($91.1 million) in a tranched series C round. Galecto CEO Hans Schambye declined to disclose details regarding the round's tranches. In...
01:38 , Jun 20, 2018 |  BioCentury  |  Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
04:19 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Galectin's NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) said galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient (HVPG) in the double-blind, U.S. Phase IIb NASH-CX trial to treat patients with non-alcoholic steatohepatitis (NASH) cirrhosis. On...
22:39 , Dec 5, 2017 |  BC Extra  |  Clinical News

Galectin sinks after NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) fell $0.76 (31%) to $1.72 on Tuesday after reporting that galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient (HVPG) in the Phase IIb NASH-CX trial to treat...
20:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of Galectin's Phase IIb NASH trial

Galectin Therapeutics Inc. (NASDAQ:GALT) said a DSMB recommended for the third time continuation of the Phase IIb NASH-CX trial evaluating galactoarabino-rhamnogalacturonate (GR-MD-02) in non-alcoholic steatohepatitis (NASH) patients with cirrhosis. Galectin said the DSMB found no...
13:02 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

TD139: Ph IIa data

Data from 24 patients with IPF in the Phase IIa portion of a double-blind, placebo-controlled, U.K. Phase Ib/IIa trial showed that once-daily inhaled TD139 for 2 weeks was well tolerated. Additional data will be presented...
13:01 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

GR-MD-02: Ph IIa data

Data from 5 patients with moderate to severe plaque psoriasis in an open-label, U.S Phase IIa trial showed that 8 mg/kg IV GR-MD-02 every other week led to an average reduction in PASI score of...
20:05 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Patient sample and mouse studies suggest inhibiting LGALS3 could help treat insulin resistance in obesity. Blood levels of LGALS3 were higher in obese patients and mice fed a high-fat diet than in lean...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS...